Login / Signup

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.

Abdul Rafeh NaqashMelissa Y Y MoeyXiao-Wei Cherie TanMehak LaharwalVanessa HillNagabhishek MokaShanda R FinniganJames MurrayDouglas B JohnsonJavid J MoslehiElad Sharon
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Increasing patient and prescriber awareness in understanding patterns of ICI-MACE and associated noncardiac irAEs should be emphasized. Better characterization of the risk of MACE with the concurrent use of non-ICI-based anticancer therapies with anti-PD-(L)1 treatments is needed.
Keyphrases
  • cancer therapy
  • drug delivery
  • case report
  • quality improvement
  • left ventricular
  • locally advanced
  • heart failure
  • squamous cell carcinoma
  • emergency department
  • adverse drug
  • electronic health record